RH

KB Home Announces the Grand Opening of Its Newest Community in Patterson, California

Retrieved on: 
Friday, June 2, 2023
Construction & Property, Urban Planning, REIT, Landscape, Interior Design, Building Systems, Architecture, Other Construction & Property, Residential Building & Real Estate, Walnut Grove Elementary School District, Multimedia, Sidney Walnut Avenue Historic District, Certification, Amazon, School, Recreation, Walking, KB, Water, Bath, Interstate Highway System, Interstate 5, RH, NYSE, KB Home

KB Home (NYSE: KBH) today announced the grand opening of Acacia at Patterson Ranch, a new community of single-story homes in popular Patterson, California.

Key Points: 
  • KB Home (NYSE: KBH) today announced the grand opening of Acacia at Patterson Ranch, a new community of single-story homes in popular Patterson, California.
  • View the full release here: https://www.businesswire.com/news/home/20230602005066/en/
    KB Home announces the grand opening of its newest community in Patterson, California.
  • Every KB home is uniquely built for each customer, so no two KB homes are the same.
  • KB homes are engineered to be highly energy and water efficient and include features that support healthier indoor environments.

Bragar Eagel & Squire, P.C. Is Investigating RH, Sanmina, and JinkoSolar and Encourages Investors to Contact the Firm

Retrieved on: 
Wednesday, May 31, 2023
P.C, Life, SANM, JKS, Bank statement, Audit committee, GAAP, Report, NYSE, Annual report, News, JinkoSolar, Cryptocurrency, Audit, RH, Sanmina Corporation

Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.

Key Points: 
  • Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
  • Additional information about each case can be found at the link provided.
  • On February 6, 2023, RH announced that it expects 2022 revenue growth at the lower end of the prior range of (3.5%) to (4.5%).
  • On this news, Sanmina's stock price fell $3.05 per share, or 5.7%, to close at $50.50 per share on May 12, 2023.

RH INVESTOR NOTICE: ROSEN, A TOP RANKED LAW FIRM, Encourages RH Investors to Inquire About Class Action Investigation – RH

Retrieved on: 
Tuesday, May 30, 2023
Titan, Bank statement, Disclosure, Advertising, Security (finance), News, NYSE, I-Space (Chinese company), Cryptocurrency, RH

The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

Key Points: 
  • The Rosen Law Firm is preparing a class action seeking recovery of investor losses.
  • WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=12982 or call Phillip Kim, Esq.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

U.S. FDA Approves Blue Earth Diagnostics’ POSLUMA® (Flotufolastat F 18) Injection, First Radiohybrid PSMA-targeted PET Imaging Agent for Prostate Cancer

Retrieved on: 
Tuesday, May 30, 2023
Science, Radiology, Biotechnology, Research, Oncology, Health, FDA, Clinical Trials, Blood pressure, CT, Disease, Emory University School of Medicine, Prostate cancer, Diarrhea, 18F, Associate professor, Winship Cancer Institute, ZERO, PSMA, Food, Food and Drug Administration, Hope, PET, Multimedia, RH, CHES, Radiopharmaceutical, Cell, Prostate, Google Images, MS, MD Anderson Cancer Center, MRI, MD, Patient, Physician, Risk, Division, University, PET/CT, Diagnosis, Recurrence, PSA, Metastasis, Safety, Medical imaging

It is the first and only FDA-approved, PSMA-targeted imaging agent developed with proprietary radiohybrid (rh) technology.

Key Points: 
  • It is the first and only FDA-approved, PSMA-targeted imaging agent developed with proprietary radiohybrid (rh) technology.
  • “This event marks a major milestone in the expansion of Blue Earth Diagnostics’ robust prostate cancer portfolio.
  • POSLUMA was developed to assist physicians in the detection and localization of prostate cancer.
  • This new approval will, ultimately, give more options – and hope – to people impacted by prostate cancer.”

RH Equity Alert: ROSEN, Globally Respected Investor Counsel, Encourages RH Investors to Inquire About Class Action Investigation - RH

Retrieved on: 
Sunday, May 21, 2023
Titan, Bank statement, Disclosure, Plaintiff, Advertising, Security (finance), News, NYSE, I-Space (Chinese company), Cryptocurrency, RH

The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

Key Points: 
  • The Rosen Law Firm is preparing a class action seeking recovery of investor losses.
  • WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=12982 or call Phillip Kim, Esq.
  • toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages RH Investors to Inquire About Class Action Investigation – RH

Retrieved on: 
Thursday, May 25, 2023
Titan, Bank statement, Disclosure, Advertising, Security (finance), News, NYSE, I-Space (Chinese company), Cryptocurrency, RH

The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

Key Points: 
  • The Rosen Law Firm is preparing a class action seeking recovery of investor losses.
  • WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=12982 or call Phillip Kim, Esq.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

RH Reports First Quarter 2023 Results

Retrieved on: 
Thursday, May 25, 2023
Entertainment, Retail, Luxury, Catalog, Home Goods, Books, Taste, Letter, NYSE, RH

RH (NYSE: RH) has released its financial results for the first quarter ended April 29, 2023, in a shareholder letter from Chairman and Chief Executive Officer Gary Friedman, available on the Investor Relations section of its website at ir.rh.com.

Key Points: 
  • RH (NYSE: RH) has released its financial results for the first quarter ended April 29, 2023, in a shareholder letter from Chairman and Chief Executive Officer Gary Friedman, available on the Investor Relations section of its website at ir.rh.com.
  • As previously announced, RH leadership will host a live conference call and audio webcast at 2:00 pm Pacific Time (5:00 pm Eastern Time) today.
  • RH (NYSE: RH) is a curator of design, taste and style in the luxury lifestyle market.
  • The Company offers collections through its retail galleries, source books, and online at RH.com, RHContemporary, RHModern.com, RHBabyandChild.com, RHTEEN.com and Waterworks.com.

RH INVESTOR NOTICE: ROSEN, A TOP RANKED LAW FIRM, Encourages RH Investors to Inquire About Class Action Investigation – RH

Retrieved on: 
Saturday, May 20, 2023
Titan, Bank statement, Disclosure, Advertising, Security (finance), News, NYSE, I-Space (Chinese company), Cryptocurrency, RH

The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

Key Points: 
  • The Rosen Law Firm is preparing a class action seeking recovery of investor losses.
  • WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=12982 or call Phillip Kim, Esq.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

RH to Report First Quarter Fiscal 2023 Financial Results on May 25, 2023

Retrieved on: 
Thursday, May 18, 2023
Catalog, Home Goods, Other Retail, Luxury, Retail, Letter, NYSE, Broadcasting, Cryptocurrency, RH

RH (NYSE: RH) today announced that it will report financial results for the first quarter fiscal 2023 ended April 29, 2023, on Thursday, May 25, 2023 after market close.

Key Points: 
  • RH (NYSE: RH) today announced that it will report financial results for the first quarter fiscal 2023 ended April 29, 2023, on Thursday, May 25, 2023 after market close.
  • RH’s first quarter fiscal 2023 financial results press release will include a shareholder letter from Chairman and Chief Executive Officer, Gary Friedman, highlighting the Company’s continued evolution and recent performance.
  • The shareholder letter and financial results will be posted to the Company’s investor relations website at ir.rh.com.
  • RH leadership will host a live conference call and audio webcast at 2:00 pm Pacific Time (5:00 pm Eastern Time) on May 25, 2023.

Blue Earth Diagnostics Announces Additional Results from Phase 3 SPOTLIGHT Trial of Investigational PET Imaging Agent 18F-rhPSMA-7.3 in Biochemical Recurrence of Prostate Cancer

Retrieved on: 
Saturday, April 29, 2023
Science, Radiology, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, DRS, Positron emission tomography, SNMMI, Prostate cancer, Diarrhea, PSMA, AUA, ASTRO, PET, Multimedia, RH, Prostate, Radiopharmaceutical, Response evaluation criteria in solid tumors, ASCO, Hypertension, Injection site reaction, Recurrence, Physician, Division, American Urological Association, NorthShore University HealthSystem, Prostate-specific antigen, Headache, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Safety, PSA, Food, Medical imaging, MD, Patient, Urology

18F-rhPSMA-7.3 is an investigational high affinity radiohybrid (rh) Prostate-Specific Membrane Antigen-targeted PET imaging agent.

Key Points: 
  • 18F-rhPSMA-7.3 is an investigational high affinity radiohybrid (rh) Prostate-Specific Membrane Antigen-targeted PET imaging agent.
  • The results were reported in a moderated poster presentation at the American Urological Association’s 2023 Annual Meeting (AUA2023), in Chicago, Ill.
  • “The utility of conventional imaging for the localization of recurrence is limited, and relapse after curative-intent radiation therapy remains a considerable clinical burden.
  • These findings from the Phase 3 SPOTLIGHT subgroup study showed high detection rates by majority read for 18F-rhPSMA-7.3 across all regions.